Supportive Care in Cancer

, Volume 21, Issue 12, pp 3307–3313 | Cite as

Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors

  • Cindy TofthagenEmail author
  • Kristine A. Donovan
  • Mary Ann Morgan
  • David Shibata
  • Yating Yeh
Original Article


Oxaliplatin is a highly neurotoxic chemotherapeutic agent routinely used for the treatment of colorectal cancer. Recent data suggest that oxaliplatin-induced peripheral neuropathy may be long-lasting; however, the effects of persistent neuropathy on colorectal cancer survivors’ physical and emotional well-being are not well understood. This cross sectional, descriptive study included persons who had received oxaliplatin-based chemotherapy for treatment of colorectal cancer at Moffitt Cancer Center between 2003 and 2010. Questionnaires including the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool, Center for Epidemiological Studies Depression Scale (CES-D), Insomnia Severity Index, Medical Outcomes Study Short Form 36, and a demographic survey were administered. Pearson’s correlations and linear regression analyses were used to examine relationships between neuropathy and depressive symptoms, sleep quality, and health-related quality of life (HRQOL). Eighty-nine percent of participants reported at least one symptom of peripheral neuropathy with a mean of 3.8 (±2.4) neuropathic symptoms. Depressive symptoms on the CES-D were significantly associated with more severe peripheral neuropathy(r = 0.38, p = 0.0001) and interference with activities (r = 0.59, p < 0.0001). Higher degrees of sleep disturbance on the Insomnia Severity Index (ISI) were significantly associated with more severe peripheral neuropathy (r = 0.35, p = 0.0004) and interference with activities(r = 0.52, p < 0.0001). HRQOL was significantly associated with peripheral neuropathy and interference with activities.


Oxaliplatin Oxaliplatin-induced peripheral neuropathy Colorectal cancer 


Conflict of interest

The primary author reports no conflict of interest, has full control of all primary data and agrees to allow the journal to review the data if requested.


  1. 1.
    ACS (2012) Cancer facts & figures 2012; Available from: Accessed June 2012
  2. 2.
    NCI (2010) FDA Approval for Oxaliplatin; Available from: Accessed June 2012
  3. 3.
    NCI (2012) Surveillance epidemiology and end results stat fact sheets; Available from: Accessed June 2012
  4. 4.
    Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389–1391PubMedCrossRefGoogle Scholar
  5. 5.
    Krishnan A et al (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51–60PubMedCrossRefGoogle Scholar
  6. 6.
    Choi J et al (2006) Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 17(1):103–105PubMedCrossRefGoogle Scholar
  7. 7.
    Park SB et al (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16(5):708–716PubMedCrossRefGoogle Scholar
  8. 8.
    Pietrangeli A et al (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13–16PubMedCrossRefGoogle Scholar
  9. 9.
    Kautio A et al (2008) Amitriptyline in the treatment of chemotherapy induced neuropathic symptoms. J Pain Symptom Manage 35(1):31–39PubMedCrossRefGoogle Scholar
  10. 10.
    Kopec J et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4(8):W1–W8Google Scholar
  11. 11.
    Tofthagen C (2010) Patient perceptions associated with chemotherapy induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28PubMedCrossRefGoogle Scholar
  12. 12.
    Gore M et al (2005) Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 30(4):374–385PubMedCrossRefGoogle Scholar
  13. 13.
    Gore M et al (2006) Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain 7(12):892–900PubMedCrossRefGoogle Scholar
  14. 14.
    Zelman DC, Brandenburg NA, Gore M (2006) Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 22(8):681–685PubMedCrossRefGoogle Scholar
  15. 15.
    Almadrones L et al (2004) Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum 31(3):615–623PubMedCrossRefGoogle Scholar
  16. 16.
    Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331PubMedCrossRefGoogle Scholar
  17. 17.
    Ostchega Y, Donohue M, Fox N (1988) High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11(1):23–32PubMedCrossRefGoogle Scholar
  18. 18.
    Tofthagen CS, McMillan SC, Kip KE (2011) Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs 34(4):E10–E20PubMedCrossRefGoogle Scholar
  19. 19.
    Radloff LS (1977) The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRefGoogle Scholar
  20. 20.
    Lewinsohn PM et al (1997) Center for epidemiologic studies depression scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging 12(2):277–287PubMedCrossRefGoogle Scholar
  21. 21.
    Morin CM (1993) Insomnia: psychological assessment and management. Guilford Press, New YorkGoogle Scholar
  22. 22.
    Savard MH et al (2005) Empirical validation of the insomnia severity index in cancer patients. Psychooncology 14(6):429–441PubMedCrossRefGoogle Scholar
  23. 23.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483PubMedCrossRefGoogle Scholar
  24. 24.
    Dunlap B, Paice JA (2006) Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4(8):398–399PubMedGoogle Scholar
  25. 25.
    Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 24(2):454–462CrossRefGoogle Scholar
  26. 26.
    Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139PubMedCrossRefGoogle Scholar
  27. 27.
    Adams RA et al (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12(7):642–653PubMedCrossRefGoogle Scholar
  28. 28.
    Argyriou AA et al (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119(2):438–444PubMedCrossRefGoogle Scholar
  29. 29.
    Argyriou AA et al (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 23(12):3116–3122CrossRefGoogle Scholar
  30. 30.
    Oshinaike O et al (2012) Influence of age and neurotoxic HAART use on frequency of HIV sensory neuropathy. AIDS Research and Treatment 2012:961510PubMedGoogle Scholar
  31. 31.
    Argyriou AA et al (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223–229PubMedCrossRefGoogle Scholar
  32. 32.
    Alejandro LM et al (2012) Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol. doi: 10.1097/COC.0b013e318246b50d Google Scholar
  33. 33.
    Lecomte T et al (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res: Off J Am Assoc Cancer Res 12(10):3050–3056CrossRefGoogle Scholar
  34. 34.
    Ruzzo A et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol 25(10):1247–1254CrossRefGoogle Scholar
  35. 35.
    Gamelin L et al (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res: Off J Am Assoc Cancer Res 13(21):6359–6368CrossRefGoogle Scholar
  36. 36.
    Cavaletti G, Alberti P, Marmiroli P (2011) Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12(12):1151–1161PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Cindy Tofthagen
    • 1
    • 2
    • 3
    Email author
  • Kristine A. Donovan
    • 4
  • Mary Ann Morgan
    • 4
  • David Shibata
    • 4
  • Yating Yeh
    • 3
  1. 1.College of NursingUniversity of South FloridaTampaUSA
  2. 2.University of Massachusetts BostonBostonUSA
  3. 3.Dana-Farber Cancer InstituteBostonUSA
  4. 4.Moffitt Cancer Center & Research InstituteTampaUSA

Personalised recommendations